8-K current report · filed Nov 4, 2026

UroGen Pharma Ltd. (URGN) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1URGN overview

Short answer

UroGen Pharma Ltd. (URGN) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

UroGen Pharma Ltd. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • ZUSDURI revenue $68.0M, up 35% quarter-over-quarter, with 331 repeat prescribers supporting commercial adoption
  • FDA accepted UGN-103 NDA, with PDUFA target date June 14, 2027, creating a potential successor and portfolio expansion
  • JELMYTO revenue fell to $21.0M from $25.7M, prompting 2026 guidance reduction to approximately $90M
  • Total revenue reached $89.0M, while net loss narrowed to $1.5M from $33.3M year-over-year
  • Cash and marketable securities declined to $90.5M, highlighting funding considerations amid $260M to $270M 2026 operating expenses

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other UroGen Pharma Ltd. 8-K filings

Get the next URGN 8-K as it lands

Follow URGN for push alerts, or ask the research agent what this filing means.